Evaluating the Safety of Dexrazoxane with Anthracyclines
Author Information
Author(s): Danyi Liu, Junting Liu, Rui Xiao, Anqi Deng, Wei Liu
Primary Institution: School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China
Hypothesis
This study aims to evaluate the actual efficacy and potential adverse effects of dexrazoxane in clinical practice by analyzing reports of adverse events related to its combination with anthracyclines.
Conclusion
Dexrazoxane can effectively alleviate anthracycline-related cardiotoxicity, but it may also increase the risk of infection, especially in children under 18.
Supporting Evidence
- Dexrazoxane significantly reduced the incidence of anthracycline-related cardiotoxicity.
- Children under 18 showed a higher likelihood of benefiting from the combination therapy.
- The combination therapy may increase the risk of infections and infestations.
Takeaway
This study looked at how a drug called dexrazoxane helps protect the heart when used with cancer treatments, but it can also make kids more likely to get infections.
Methodology
The study used four disproportionality analysis methods to analyze adverse event reports from the FAERS database from Q3 2014 to Q1 2024.
Potential Biases
There may be biases in the reporting of adverse events due to the voluntary nature of the FAERS database.
Limitations
The study's findings may be limited by the spontaneous reporting nature of the FAERS database, which can lead to under-reporting and variability in report quality.
Participant Demographics
The study included reports from both children and adults, with a significant number of reports from patients under 18 years old.
Statistical Information
Confidence Interval
95% CI
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website